News | September 25, 2022
Aptar Pharma collaborates with Fluidda
The companies will leverage their respective proprietary technology platforms
The companies will leverage their respective proprietary technology platforms
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
Dupixent peak sales ambition raised to more than €13 billion
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Subscribe To Our Newsletter & Stay Updated
